Eton Pharmaceuticals, Inc. ETON Interest Income (Expense), Nonoperating

Interest Income (Expense), Nonoperating at other companies

ANI PharmaceuticalsANIP

——

Acadia PharmaceuticalsACAD

——

PTC TherapeuticsPTCT

——

Other financials

Income statement

See full

Revenue$24.3M+40.4%

Gross profit$14.7M+49.4%

Operating income$2.4M+614%

Net income$1.6M+199%

EPS (diluted)$0.05+183%

Balance sheet

See full

Cash & equivalents$19.7M+12.9%

Total debt$31.3M+3.7%

Total equity$30.6M+25.2%

Total assets$97.7M+16.3%

Cash flow

See full

Operating cash flow$7.4M+254%

CapEx$75.0K—

Free cash flow$7.3M+251%

Valuation

See full

Market cap$930.79M+156%

Enterprise value$942.39M+150%

P/S10.7×+3.2×

Profitability

See full

Gross margin54.8%-3.7pp

Operating margin-15.1%—

Net margin-9.5%-2.7pp

FCF margin17.1%—

Returns & leverage

See full

Return on equity-34.2%+0.9pp

Debt / equity1×-0.2×

Current ratio1.2×-0.8×

Where this comes from

Reported directly by Eton Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.

The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eton Pharmaceuticals, Inc.'s interest income (expense), nonoperating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s interest income (expense), nonoperating?: Eton Pharmaceuticals, Inc. (ETON) reported interest income (expense), nonoperating of -$840K in Q1 2026.
How has Eton Pharmaceuticals, Inc.'s interest income (expense), nonoperating changed year-over-year?: Eton Pharmaceuticals, Inc.'s interest income (expense), nonoperating increased by 18.3% year-over-year, from -$1.03M to -$840K.